证券代码：300485 证券简称：赛升药业 公告编号：2025-042 北京赛升药业股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东大会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、部门 规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 11 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 11 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 11 月 11 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：202 ...

证券代码：300485 证券简称：赛升药业 公告编号：2025-038 北京赛升药业股份有限公司 第五届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北京赛升药业股份有限公司（以下简称"公司"）第五届监事会第十次会议 于 2025 年 10 月 22 日在公司会议室召开，本次会议于 2025 年 10 月 17 日以通讯 的方式向所有监事送达了会议通知。会议应参会监事 3 人，实际参会监事 3 人， 公司董事会秘书列席会议。会议由监事会主席赵丽娜女士主持。本次会议的召开 符合《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件 和公司章程的规定，会议决议合法、有效。 二、会议审议情况 经全体监事认真审议并表决，会议通过了以下议案： 1、审议通过《关于公司<2025年第三季度报告>的议案》 经审核，公司《2025 年第三季度报告》的编制程序符合法律、法规和中国 证监会的有关规定，报告内容真实、准确、完整地反映了公司的实际情况，不存 在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：赞成 3 票、反对 ...

北京赛升药业股份有限公司 第五届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北京赛升药业股份有限公司（以下简称"公司"）第五届董事会第十次会议 于2025年10月22日在公司会议室召开，本次会议于2025年10月17日以通讯的方式 向所有董事送达了会议通知。应参与会议董事8名，实际参会董事8人，会议由董 事长马骉主持，公司监事、高级管理人员列席了本次会议。本次会议的召开符合 《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定，会议决议合法、有效。 二、会议审议情况 经全体董事认真审议并表决，会议通过了以下议案： 1、审议通过《关于公司<2025年第三季度报告>的议案》 公司《2025 年第三季度报告》的编制程序符合法律、法规和中国证监会的 有关规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚 假记载、误导性陈述或者重大遗漏。具体内容详见中国证监会指定的创业板信息 披露网站巨潮资讯网（http://www.cninfo.com.cn）。 证券代码：300485 ...

Group 1 - The core viewpoint of the announcement indicates that the company's third-quarter revenue reached 112 million yuan, representing a year-on-year increase of 3.50% [1] - The net profit for the third quarter was 4.0733 million yuan, showing a significant decline of 41.41% compared to the previous year [1] - For the first three quarters, the total revenue amounted to 309 million yuan, which reflects a year-on-year decrease of 4.41% [1] - The net profit for the first three quarters was 51.8596 million yuan, marking a substantial increase of 152.81% year-on-year [1]

北京赛升药业股份有限公司 2025 年第三季度报告 证券代码：300485 证券简称：赛升药业 公告编号：2025-039 北京赛升药业股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 □是 ☑否 1 北京赛升药业股份有限公司 2025 年第三季度报告 一、主要财务数据 公司是否需追溯调整或重述以前年度会计数据 □是 ☑否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 111,825,972.85 | 3.50% | 308,627,146 ...

Core Insights - The biopharmaceutical sector experienced a slight increase of 0.13% on October 16, with Sanofi leading the gains [1] - The Shanghai Composite Index closed at 3916.23, up 0.1%, while the Shenzhen Component Index closed at 13086.41, down 0.25% [1] Biopharmaceutical Sector Performance - Sanofi (688336) saw a significant rise of 13.02%, closing at 59.90 with a trading volume of 177,400 shares and a transaction value of 1.063 billion [1] - Other notable gainers included: - Nossland (920047) up 4.09% to 25.46 with a transaction value of 125 million [1] - Rongchang Bio (688331) up 3.28% to 99.20 with a transaction value of 684 million [1] - Conversely, several companies experienced declines, including: - Anke Bio (300009) down 2.48% to 10.23 with a transaction value of 315 million [2] - Kain Technology (688687) down 1.92% to 28.62 with a transaction value of 169 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 2.7582 million from institutional investors, while retail investors experienced a net outflow of 140 million [2] - Notable capital inflows included: - Junshi Biosciences (688180) with a net inflow of 71.7936 million from institutional investors [3] - Sanofi (688336) with a net inflow of 67.508 million from institutional investors [3] - Conversely, significant outflows were observed in: - Sanofi (688336) with a retail net outflow of 540,300 [3] - Rongchang Bio (688331) with a retail net outflow of 4.41034 million [3]

Core Insights - The biopharmaceutical sector experienced a rise of 1.78% on October 15, with Sai Sheng Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Company Performance - Sai Sheng Pharmaceutical (300485) closed at 12.28, with a gain of 9.16% and a trading volume of 369,300 shares [1] - Kanghua Biological (300841) closed at 77.71, up 6.02%, with a trading volume of 49,400 shares [1] - Kangchen Pharmaceutical (603590) closed at 49.11, increasing by 5.84%, with a trading volume of 40,700 shares [1] - San Sheng Guo Jian (688336) closed at 53.00, up 5.68%, with a trading volume of 56,800 shares [1] - Bai Pu Sai Si (301080) closed at 57.73, gaining 5.23%, with a trading volume of 28,000 shares [1] - Rongchang Biological (688331) closed at 96.05, up 5.20%, with a trading volume of 72,700 shares [1] - Shenzhou Cell (688520) closed at 55.03, increasing by 4.90%, with a trading volume of 42,700 shares [1] - Kang Le Wei Shi (920575) closed at 12.94, up 4.61%, with a trading volume of 53,900 shares [1] - Tonghua Dongbao (600867) closed at 8.96, gaining 4.55%, with a trading volume of 543,800 shares [1] - Olin Biological (61688919) closed at 24.96, up 4.22%, with a trading volume of 65,800 shares [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 331 million yuan from institutional investors, while retail investors experienced a net outflow of 234 million yuan [2] - The main funds showed a net inflow in several companies, including Changchun High-tech (000661) with 66.94 million yuan and Tonghua Dongbao (600867) with 62.56 million yuan [3] - Retail investors showed significant outflows in companies like Sai Sheng Pharmaceutical (300485) with 50.24 million yuan and Rongchang Biological (688331) with 38.34 million yuan [3]

证券日报网讯赛升药业10月13日在互动平台回答投资者提问时表示，截至2025年9月30日，公司股东户 数为33373户。 （文章来源：证券日报） ...

Core Insights - The company, Sai Sheng Pharmaceutical, reported that as of September 19, 2025, the number of shareholders is 33,991 [2] Company Summary - Sai Sheng Pharmaceutical has a total of 33,991 shareholders as of the specified date [2]

Group 1 - The core point of the news is that Sai Sheng Pharmaceutical (300485.SZ) announced a share reduction plan by its controlling shareholders and actual controllers, which will not affect the company's control or governance structure [1] - The shareholders, Ma Li and Liu Shuqin, plan to reduce their holdings by up to 9,633,328 shares, representing 2% of the total share capital of 481,666,400 shares, within a three-month period starting from October 21, 2025 [1] - The estimated cash amount from the share reduction is approximately 116 million yuan, based on the closing price of 12.08 yuan on September 19, 2025 [1] Group 2 - In 2024, Sai Sheng Pharmaceutical reported operating revenue of 416.48 million yuan, a decrease of 12.61% compared to 2023 [2][3] - The net profit attributable to shareholders was -68.85 million yuan, a decline of 166.90% from the previous year, where it was 102.92 million yuan [2][3] - The net profit after deducting non-recurring gains and losses was 11.76 million yuan, showing a significant improvement of 127.94% compared to the previous year's loss of 42.09 million yuan [2][3] - The net cash flow from operating activities reached 135.97 million yuan, an increase of 541.05% year-on-year [2][3]